Jesse Hollingsworth has left Dendreon to join AP Pharma as VP of sales.
The appointment comes as AP Pharma prepares to advance its lead product APF350, which is intended for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting.
“Over the past several months, AP Pharma has been focused on recruiting key additions to our management team, and Jesse’s experience in oncology sales will provide insights into the sales progamme for … APF350,” said Robert Rosen, AP Pharma’s chief commercial officer.
This experience includes Hollingsworth’s time as senior director of group purchasing organisation and trade strategy at Dendreon, which developed the prostate cancer vaccine Provenge.
Prior to this role, Hollingsworth was senior director of strategic business development and marketing at ION Solutions.
This was preceded by a period as marketing director for the oncology business unit of Amgen, where he worked on such products as Neulasta, Neupogen and Vectibix.